So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

SINGAPORE—China is racing toward economic self-sufficiency by weaning itself off American technology. But it has made a ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

As geopolitical tensions prompt global pharmaceutical giants to pivot away from China, India's Contract Development and ...

The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

Mayur Maheshwari, CEO of UPSIDA, said the Bulk Drug Pharma Park would be important in reducing India's dependence on China ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed ...